- Stocks
- Healthcare
- NYSE: BSX

Price (delayed)

$44.46

Market cap

$63.3B

P/E Ratio

120.16

Dividend/share

N/A

EPS

$0.37

Enterprise value

$69.74B

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology,

Boston Scientific's gross profit has increased by 14% QoQ and by 8% YoY

The revenue has increased by 11% from the previous quarter and by 10% YoY

The EPS has soared by 164% from the previous quarter but it has plunged by 87% YoY

Boston Scientific's net income has surged by 135% QoQ but it has shrunk by 85% YoY

The P/E is 13% above the 5-year quarterly average of 106.5

What are the main financial stats of BSX

Market
Valuations
Earnings

Shares outstanding

1.42B

Market cap

$63.3B

Enterprise value

$69.74B

Price to earnings (P/E)

120.16

Price to book (P/B)

3.96

Price to sales (P/S)

5.64

EV/EBIT

77.23

EV/EBITDA

27.27

EV/Sales

6.23

Revenue

$11.2B

EBIT

$903M

EBITDA

$2.56B

Free cash flow

$1.95B

Per share
Balance sheet
Liquidity

EPS

$0.37

Free cash flow per share

$1.37

Book value per share

$11.22

Revenue per share

$7.88

TBVPS

$10.21

Total assets

$31.17B

Total liabilities

$15.23B

Debt

$9.11B

Equity

$15.94B

Working capital

$2.69B

Debt to equity

0.57

Current ratio

1.66

Quick ratio

1.07

Net debt/EBITDA

2.52

Margins
Efficiency
Dividend

EBITDA margin

22.8%

Gross margin

66.9%

Net margin

5.2%

Operating margin

4.2%

Return on assets

1.7%

Return on equity

3.4%

Return on invested capital

5.1%

Return on capital employed

3.3%

Return on sales

8.1%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Boston Scientific stock price performed over time

Intraday

-0.54%

1 week

1.88%

1 month

-0.76%

1 year

19.07%

YTD

23.67%

QTD

3.98%

How have Boston Scientific's revenue and profit performed over time

Revenue

$11.2B

Gross profit

$7.49B

Operating income

$469M

Net income

$582M

Gross margin

66.9%

Net margin

5.2%

BSX's operating margin has surged by 200% since the previous quarter but it is down by 36% year-on-year

Boston Scientific's net income has surged by 135% QoQ but it has shrunk by 85% YoY

Boston Scientific's net margin has surged by 117% QoQ but it has shrunk by 87% YoY

Boston Scientific's operating income has decreased by 30% YoY

What is Boston Scientific's growth rate over time

What is Boston Scientific stock price valuation

P/E

120.16

P/B

3.96

P/S

5.64

EV/EBIT

77.23

EV/EBITDA

27.27

EV/Sales

6.23

The EPS has soared by 164% from the previous quarter but it has plunged by 87% YoY

The P/E is 13% above the 5-year quarterly average of 106.5

The stock's price to book (P/B) is 17% less than its 5-year quarterly average of 4.8 but 14% more than its last 4 quarters average of 3.5

The equity has grown by 2.1% YoY

BSX's P/S is 18% above its 5-year quarterly average of 4.8 and 5% above its last 4 quarters average of 5.4

The revenue has increased by 11% from the previous quarter and by 10% YoY

How efficient is Boston Scientific business performance

The return on equity has surged by 162% since the previous quarter but it has dropped by 89% year-on-year

The return on assets has surged by 143% since the previous quarter but it has dropped by 87% year-on-year

BSX's ROIC has soared by 132% YoY and by 59% from the previous quarter

The ROS has soared by 119% YoY and by 42% from the previous quarter

What is BSX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for BSX.

How did Boston Scientific financials performed over time

Boston Scientific's total assets is 105% more than its total liabilities

BSX's current ratio is down by 11% year-on-year and by 8% since the previous quarter

BSX's quick ratio is up by 4.9% year-on-year

Boston Scientific's debt is 43% lower than its equity

Boston Scientific's debt to equity has decreased by 7% YoY

Boston Scientific's debt has decreased by 4.4% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.